New real-life evidence from a UK observational study, presented at ISTH 2015, reveals the burden and mortality of venous thromboembolism (VTE) in patients with active cancer over a 10 year period1,3. Key findings from the study underscore the need for improved blood clot management in these patients:

  •  VTE is common in patients with active cancer: During the study period, 6,592 VTEs were observed (46.3% deep vein thrombosis (DVT) and 53.7% pulmonary embolism (PE) with or without DVT). VTE incidence rate in the active-cancer cohort was 54-times higher than in the non-active cancer cohort1 (Abstract OR294)
  • Patients with active cancer are at increased risk of recurrent VTEs: 591 patients suffered recurrent VTEs (48.4% DVT and 51.6% PE). VTE recurrence incidence rates were maximal in the first 6 months and twice as high as non-active cancer patients 2 (Abstract AS084)
  • Risk of mortality following VTE is considerable and depends on the site of active cancer3 (Abstract PO124-TUE)

Efforts are needed to prevent and treat VTE and reduce the risk of VTE recurrence in patients with active cancer1,2. The recently-announced CALLISTO Clinical Research Programme will explore the potential benefits of rivaroxaban for the prevention and treatment of PE and DVT in patients with various types of cancer.

 

 

By |June 25, 2015